Amphastar Pharmaceuticals (AMPH) Earning Somewhat Positive News Coverage, Accern Reports

News headlines about Amphastar Pharmaceuticals (NASDAQ:AMPH) have trended somewhat positive on Wednesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 43.8128324390409 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at $18.42 on Wednesday. Amphastar Pharmaceuticals has a twelve month low of $12.05 and a twelve month high of $19.95. The company has a quick ratio of 1.86, a current ratio of 3.08 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $863.42, a P/E ratio of 125.20, a PEG ratio of 1.32 and a beta of 1.51.

AMPH has been the subject of a number of recent research reports. Zacks Investment Research cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 27th. Jefferies Group set a $19.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Raymond James Financial cut Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 target price for the company. in a report on Thursday, November 9th. BMO Capital Markets increased their target price on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a report on Friday, November 10th. Finally, Needham & Company LLC increased their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $20.83.

In related news, CFO William J. Peters sold 6,226 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $19.67, for a total transaction of $122,465.42. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Stephen B. Shohet sold 7,862 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $18.34, for a total value of $144,189.08. Following the sale, the director now owns 31,978 shares in the company, valued at $586,476.52. The disclosure for this sale can be found here. Over the last three months, insiders sold 58,673 shares of company stock valued at $1,124,573. 11.10% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/21/amphastar-pharmaceuticals-amph-earning-somewhat-positive-news-coverage-accern-reports.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply